Selective Cyclooxygenase Inhibitors

David B. Reitz, Karen Seibert

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


The significant advances made in recent years in the discovery of selective cyclooxygenase inhibitors has been impressive. The current availability of human recombinant COX-1 and COX-2 assays used in determining enzyme selectivity has facilitated the discovery and development of selective COX-2 inhibitors as therapeutic agents for the treatment of inflammation. Since no clinical data has been reported to date, it is unknown whether selective COX-2 inhibitors will have genuine therapeutic utility in the treatment of inflammation without the gastric aide-eff ects associated with non-selective cyclooxygenase inhibitors (NSAIDs).

Original languageEnglish
Pages (from-to)179-188
Number of pages10
JournalAnnual Reports in Medicinal Chemistry
Issue numberC
StatePublished - Jan 1 1995


Dive into the research topics of 'Selective Cyclooxygenase Inhibitors'. Together they form a unique fingerprint.

Cite this